André Caiado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
André Caiado has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Anabela Rodrigues
Serviço de Imuno-Hemoterapia, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal
2 shared publications - António Robalo Nunes
Hospital de Dia de Imuno-Hemoterapia, Hospital Pulido Valente, Centro Hospitalar Lisboa Norte (CHLN), Alameda das Linhas de Torres 117, 1769-001 Lisboa, Portugal
2 shared publications - Teresa Sevivas
Más que un juego de niños: trombosis pediátrica en el Serviço de Imuno-hemoterapia Sociedad Española de Trombosis y Hemostasia (SETH) y Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis (CLAHT) Unidade Local de Saúde de Coimbra Hospital Pediátrico 2938-8740 / Coimbra Portugal
2 shared publications - Carla Leal Pereira
Transfusion Medicine Department. Hospital Santa Maria. Centro Hospitalar Universitário Lisboa Norte. Lisbon
1 shared publication
Latest Publications
- 4 January 2021
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 34 (1) , 44-55
Viscoelastic Tests in the Evaluation of Haemostasis Disturbances in SARS-CoV2 Infection
COVID-19 associated coagulopathy is a dysfunction of severe SARS-CoV-2 infection, characterized by significantly increased fibrinogen, D-dimer and C reactive protein and normal to near-normal prothrombin time, activated partial thromboplastin time and platelet count. Hypercoagulopathy and hypofibrinolysis coexist and are detected by viscoelastic tests. These features, when associated with immobilization and intrinsic risk factors (age, obesity, comorbidities, drugs) of the patient, can trigger thromboembolic events, despite thromboprophylaxis. The lungs are the first and most severely damaged organ. To date, most patients have exhibited hypercoagulability on viscoelastic tests not detected by standard coagulation tests. A high rate of thrombotic events was reported, suggesting that it should be considered as a cause of clinical deterioration in intensive care and potentially other clinical settings. In advanced stage, COVID-19 associated coagulopathy, fibrinogen and platelet count can decrease significantly, depending on the severity of clinical status resembling consumptive coagulopathy. In this stage, bleeding events can occur, especially if the patient is under extracorporeal membrane oxygenation (ECMO). Viscoelastic tests are very useful tools to assess hypercoagulability and hypofibrinolysis (not detectable by standard coagulation tests) in critically ill SARS-CoV-2 patients with COVID-19 associated coagulopathy and look like very promising tools for anticoagulation management. However, further research needs to be carried out to determine whether abnormal viscoelastic tests alone or in combination with other clinical or laboratory findings can identify patients at increased thrombotic risk. Clinical trials to evaluate hypercoagulability using viscoelastic tests and the need for personalized dosage of anticoagulation in SARS-CoV-2 patients are quickly emerging.
- 4 January 2021
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 34 (1) , 44-55
Viscoelastic Tests in the Evaluation of Haemostasis Disturbances in SARS-CoV2 Infection
COVID-19 associated coagulopathy is a dysfunction of severe SARS-CoV-2 infection, characterized by significantly increased fibrinogen, D-dimer and C reactive protein and normal to near-normal prothrombin time, activated partial thromboplastin time and platelet count. Hypercoagulopathy and hypofibrinolysis coexist and are detected by viscoelastic tests. These features, when associated with immobilization and intrinsic risk factors (age, obesity, comorbidities, drugs) of the patient, can trigger thromboembolic events, despite thromboprophylaxis. The lungs are the first and most severely damaged organ. To date, most patients have exhibited hypercoagulability on viscoelastic tests not detected by standard coagulation tests. A high rate of thrombotic events was reported, suggesting that it should be considered as a cause of clinical deterioration in intensive care and potentially other clinical settings. In advanced stage, COVID-19 associated coagulopathy, fibrinogen and platelet count can decrease significantly, depending on the severity of clinical status resembling consumptive coagulopathy. In this stage, bleeding events can occur, especially if the patient is under extracorporeal membrane oxygenation (ECMO). Viscoelastic tests are very useful tools to assess hypercoagulability and hypofibrinolysis (not detectable by standard coagulation tests) in critically ill SARS-CoV-2 patients with COVID-19 associated coagulopathy and look like very promising tools for anticoagulation management. However, further research needs to be carried out to determine whether abnormal viscoelastic tests alone or in combination with other clinical or laboratory findings can identify patients at increased thrombotic risk. Clinical trials to evaluate hypercoagulability using viscoelastic tests and the need for personalized dosage of anticoagulation in SARS-CoV-2 patients are quickly emerging.
- Open Access
- 27 June 2020
- Published by Sociedade Portuguesa de Medicina Interna in Medicina Interna
- Vol. 27 (2) , 181-185
Abordagem da Hemostase e Anticoagulação no Contexto da Infeção Por SARS-CoV-2
- 27 June 2020
- Published by Sociedade Portuguesa de Medicina Interna in Medicina Interna
- Vol. 27 (2) , 181-185
Open AccessAbordagem da Hemostase e Anticoagulação no Contexto da Infeção Por SARS-CoV-2